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Abstract
Goal: To longitudinally investigate sexual functioning in testicular cancer patients during the
ﬁrst year, and examine the eﬀect of relationship status (with a partner or single) and depressive
symptoms on sexual functioning.
Patients and methods: 93 testicular cancer patients (39% single) treated in two large
referral centers for testicular cancer ﬁlled in the International Index of Erectile Function
(IIEF) and CES-D after orchiectomy (T1) and 3 (T2) and 12 (T3) months later.
Results: Orgasmic functioning, overall satisfaction and total sexual functioning decreased
between T1 and T2 and increased to an above T1 level at T3. Levels of erectile functioning and
intercourse satisfaction were higher at T3 than at T1 and T2. Desire remained stable. Type of
treatment did not aﬀect sexual functioning. Singles reported worse sexual functioning at all
measurement times than committed patients, and comparable desire. One year after surgery,
singles also reported worse sexual functioning on three domains when compared with norms.
Depressive symptoms were highest and signiﬁcantly but weakly related to one domain of sexual
functioning at T1, to three domains at T2, and to none at T3. Early depressive symptoms had
small to moderate predictive power on sexual functioning at T2, but not at T3.
Conclusion: Sexual functioning, but not desire, ﬂuctuates during the ﬁrst year after
testicular cancer. Type of treatment and depressive symptoms were no risk factors for sexual
dysfunction in the longer term. Singles reported more sexual problems than patients in a
relationship and norms, they may need more information and guidance concerning their sexuality.
Copyright r 2009 John Wiley & Sons, Ltd.
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Introduction
Testicular cancer is rare (1% of new cancer
diagnoses in men), but the most frequent malig-
nancy in young men aged between 15 and 40 years.
The highest incidence lies around 30 years of age.
Testicular cancer is highly curable, with approxi-
mately 95% of men surviving the disease [1,2].
Sexual functioning in testicular cancer patients and
survivors has received attention before. This is not
surprising, as this type of cancer involves an organ
associated with sexuality, and strikes at a young
age when sexuality is of great importance. Testi-
cular cancer patients can experience sexual pro-
blems after diagnosis and completion of treatment,
which in combination with other physical and
psychological consequences, can aﬀect global
quality of life [3,4].
Previous research shows that a varying percen-
tage of testicular cancer survivors suﬀer from
several physical sexual problems such as ejacula-
tory failure, orgasmic problems, and erectile
dysfunction (all reported up to 40%) [5–7]. In
contrast, some studies showed that the prevalence
of erectile dysfunction after testicular cancer is
similar to that found in the general population
[3,8]. In addition to physical sexual problems, a
considerable percentage of survivors also report
psychosexual dysfunction after treatment like
decreased desire, decreased sexual activity and
dissatisfaction. Sexual dysfunction was reported
to persist for up to 2 years after treatment, after
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which functioning seems to recover [5,6]. A major
pitfall of most studies is that they suﬀer from
methodological shortcomings such as using stan-
dardized questionnaires, normative data or retro-
spective measurements [5,6]. A more recent study
did compare sexual functioning in testicular cancer
survivors to functioning in a norm group [9].
Results indicated that survivors experienced more
problems with sexual drive, erection and ejacula-
tion than men in the norm group. However, young
survivors (20–39 years) reported more sexual
satisfaction than their normative counterparts. It
remains unclear why some survivors develop and
continue to have sexual problems, while others
do not. It is therefore useful to gain insight to
possible risk factors for the development of sexual
dysfunction.
A possible risk factor might be the relationship
status of patients. In general, married men appear
to experience a better quality of life than single
men, and this might include sexual functioning as
well [10]. As testicular cancer patients are relatively
young, a signiﬁcant number will not yet have
established a steady relationship and is therefore
single. Most studies indicated that around 70% of
participating testicular cancer survivors was in
a committed relationship when diagnosed [11].
A review study indicated that little attention has
been paid to the eﬀect of relationship status on
functioning in testicular cancer patients and
survivors [12]. The few studies that addressed this
subject showed that testicular cancer survivors in
relationships established after completion of treat-
ment reported less sexual satisfaction than men in
the general population, and than testicular cancer
survivors who had the same partner as at the time
of diagnosis [13]. It was also found that testicular
cancer survivors who did not have a partner were
more likely to report sexual problems, deﬁned by
drive, erection and ejaculation problems, or a
satisfaction problem compared with survivors
who did have a partner [9]. Contradictory to these
ﬁndings was the ﬁnding that sexual functioning in
testicular cancer patients was similar in men with a
partner and singles. However, married men seemed
somewhat more worried about changes in their
appearance and attractiveness, and an earlier study
found that 24% of married survivors perceived
themselves to be less attractive as a result of their
treatment [14,15]. These contradictory ﬁndings
make it of interest to take relationship status as a
risk factor into account for sexual dysfunction.
A second risk factor may be depression. It has
been suggested that the emotional impact of
testicular cancer may be a more important
predictor of sexual dysfunction than objective
physical and treatment aspects [5,16]. Psychosexual
functioning seems to be aﬀected by the experience
but independently of type of treatment [5,9,16–18].
Psychological responses to diagnosis and treatment
should therefore be taken into account when
studying sexual functioning. However, very little
attention has been paid to the relationship between
emotional distress and sexual dysfunction in this
group [6]. Depressive symptoms are prevalent in
cancer patients, with reported rates varying
between 15–and 24% [19,20]. Depression appears
to be prevalent in 9–11% of testicular cancer
survivors up to 5 years after treatment completion
[21] and is unrelated to age at diagnosis, type of
treatment or marital status at diagnosis. Depres-
sion is well known to be related to sexual
dysfunction, with the majority of (not cancer
related) depressed patients reporting sexual dys-
function. It is associated with decreased libido,
decreased frequency of intercourse, erectile dys-
function and delayed or absent orgasm, indepen-
dent from use of antidepressant drugs [22]. A study
on long-term testicular cancer survivors (median
number of years since treatment 3.9) showed that
severely impaired sexual functioning was related to
more depression and fatigue [18].
To advance on existing research, the present
two-center study focused on sexual functioning in
testicular cancer patients during the ﬁrst year after
orchiectomy (removal of the aﬀected testicle), using
standardized questionnaires. The eﬀect of relation-
ship status, type of treatment and depressive
symptoms on sexual functioning were taken into
account. Main research aims were to examine: the
trajectory of sexual functioning during the ﬁrst
year after removal of the aﬀected testis; diﬀerences
in sexual functioning on the basis of type of
treatment received and relationship status; the
eﬀect of depressive symptoms on sexual function-
ing concurrently and prospectively.
Methods
Patients and procedure
This study was part of a larger study on the
possible negative eﬀects of chemotherapy after
testicular cancer. As chemotherapy is a treatment
option after diagnosis of non-seminomatous
testicular tumors, only patients with this diagnosis
were included. Two patient groups diagnosed
with a non-seminomatous testicular tumor were
approached for participation.
The ﬁrst group consisted of all patients referred
to the University Medical Center Groningen
(UMCG) in The Netherlands for treatment be-
tween April 2001 and March 2004. Exclusion
criteria were age younger than 18 years at study
entry, a psychiatric illness or history involving
formal thought disorders, insuﬃcient command of
the Dutch language, prior neurologic illness, and
previous treatment for cancer. The study was
approved by the Medical Ethics Committee of the
UMCG. The second group consisted of all patients
Copyright r 2009 John Wiley & Sons, Ltd. Psycho-Oncology 19: 238–247 (2010)
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consecutively visiting the MD Anderson Cancer
Center (MDACC) in Houston, TX for treatment
between December 1999 and December 2002. The
study was approved by the Institutional Review
Board of the MDACC. Exclusion criteria were age
younger than 18 years at study entry, a psychiatric
illness or history, insuﬃcient command of the
English language, inability to give informed con-
sent, prior neurologic illness, and an extragonadal
germ cell tumor.
Orchiectomy is both therapeutic and diagnostic:
a conclusive diagnosis of testicular cancer results
from pathology assessment of the removed testicle.
Therefore, the study was introduced to patients
after orchiectomy in both institutions. Patients
received oral and written information about the
study from co-workers of the study, together with
an informed consent form. Patients who agreed to
participate, received a self-report questionnaire at
three time points: after orchiectomy but before the
start of chemotherapy (T1), immediately after
chemotherapy completion or 3 months after T1
(T2), and 1 year after T1 (T3). At both hospitals T1
and T2 questionnaires were completed in the
hospital. At the MDACC patients ﬁlled in the T3
questionnaire at the hospital as well, at the UMCG
T3 questionnaire and a prepaid return envelope
were sent to the patients’ home address.
Instruments
Information on age, educational level, daily occu-
pation, proposed type of treatment and relation-
ship status (dichotomized into the categories ‘with
a partner’ (married or in a committed relationship)
and ‘single’) were collected at T1. Daily occupation
was dichotomized into the categories ‘employed for
wages’ (including self-employed) and ‘not em-
ployed for wages’ consisting of students, being
unemployed, and being unable to work. On T3,
information on type of treatment received was
retrieved from the patients’ medical ﬁles. Dutch
educational level was measured on a 7-point scale:
‘Elementary school’ (1), ‘Lower technical/voca-
tional degree’ (2), ‘High school-low level’ (3),
‘Middle level technical/vocational degree’ (4),
‘High school-high level’ (5), ‘Higher technical/
vocational degree’ (6), and ‘University degree’ (7).
American educational level was measured on a
7-point scale also, using the following levels: ‘Never
received a high school diploma/GED’ (1), ‘High
school diploma/GED’ (2), ‘Technical/vocational
degree’ (3), ‘Some college level credits or 2 years
college degree’ (4), ‘Bachelors degree’ (5), ‘Masters
degree’ (6), and ‘M.D., Ph.D., or advance
degree’ (7). Because both countries measured
education according to a 7-point scale, and higher
scores indicated more years of education we treated
education level as a continuous variable. Type
of treatment consisted of orchiectomy only,
orchiectomy and chemotherapy, or orchiectomy,
chemotherapy and resection of residual retroper-
itoneal tumor mass (RRRTM). Patients of the
UMCG group received four cycles of bleomycin,
etoposide and cisplatin (BEP), with a 3-week
interval between each cycle. Chemotherapy regi-
men in the MDACC group ranged from one to
seven cycles, depending on stage, tumor markers,
and response. BEP was the most commonly
administered regimen, but several patients received
CISCA/VB (cyclophosphamide, adriamycin, cis-
platin, vinblastine, and bleomycin), or BOP (vin-
cristine, bleomycin, and cisplatin)/CISCA/POMB
(vincristine, methotrexate, and bleomycin)/ACE
(etoposide, actinomycin, and cyclophosphamide).
Strategies for treatment following chemotherapy
are comparable at the UMCG and the MDACC.
All patients with disseminated testicular cancer and
residual disease after chemotherapy with mas-
ses41 cm on a CT scan underwent an exploratory
laparatomy and RRRTM [23]. All patients with a
mature component in the primary testicular tumor
underwent an exploratory laparatomy as well to
ensure that all potential metastatic disease was
resected [24].
Sexual functioning was measured using the
International Index of Erectile Function (IIEF), a
widely used, multi-dimensional self-report instru-
ment for the evaluation of male sexual function
[25,26]. The IIEF consists of ﬁve subscales: erectile
function (six items), orgasmic function (two items),
sexual desire (two items), intercourse satisfaction
(three items), and overall satisfaction (two items),
and provides a total score (sum of all items).
Normscores are available from 109 male volunteers
(mean age 55 years, range 29–76) without a history
of sexual dysfunction. Items were scored with
diﬀerent value labels on a 5- or 6-point scale, and
9 items were scored 0 when the patient had not
been sexually active. A mean score for each
subscale was calculated and higher scores indicated
better functioning. Reliability of the IIEF in the
UMCG group was adequate for all subscales (as
ranged from 0.86 to 0.98 over the three measure-
ment times). Reliability for the IIEF in the
MDACC group was good for all subscales (as
ranged from 0.86 to 0.95 over the three measure-
ment times), except for the a for orgasmic function
at T3, which was somewhat lower (0.69).
Depression was measured with the center
for epidemiological studies—depression scale
(CES-D), a 20-item questionnaire that measures
depressive symptoms during the past week. Items
are scored on a 4-point scale ranging from seldom
or never (0), sometimes or a little (1), regularly (2),
to most of the time or always (3). Scores are
summed, resulting in a possible total score ranging
from 0 to 60. A score of 16 or above suggests
clinically signiﬁcant depressive symptoms. The
CES-D shows good internal validity and reliability
240 M. A. Tuinman et al.
Copyright r 2009 John Wiley & Sons, Ltd. Psycho-Oncology 19: 238–247 (2010)
DOI: 10.1002/pon
[27], also in cancer patients [20]. In the present
study Cronbach’s as for the UMCG group ranged
from 0.89–0.91, and for the MDACC group from
0.88–0.91.
Statistical analyses
Independent measures t-tests and w2 test were
performed to examine diﬀerences in sociodemo-
graphics and type of treatment between patient
groups according to nationality and relationship
status. The cut-oﬀ score of the CES-D was used to
identify patients who were experiencing clinically
signiﬁcant depressive symptoms. Repeated mea-
sures analyses of variance were computed to
examine change over time in the ﬁve domains of
sexual functioning and depressive symptoms; ﬁrstly
with relationship status and secondly with type of
treatment (three groups) as between-group factor.
Relevant covariates were entered to control for
diﬀerences between groups. Independent t-test was
performed to examine diﬀerences between sexual
functioning of respondents at T3 and that of the
normgroup. Eﬀect sizes were calculated using
Cohen’s d to assess the clinical signiﬁcance of
diﬀerences found over time and of comparison with
norm. Eﬀect sizes lower than 0.20 indicate negli-
gible diﬀerences, eﬀect sizes between 0.20 and 0.50
indicate a small diﬀerence, and those between 0.50
and 0.80 a moderate diﬀerence. A large eﬀect size
(X0.80) can be seen as a clinically important
diﬀerence [28].
Partial pearson correlations were used to exam-
ine relationships between sexual functioning and
depressive symptoms, concurrently (within time,
T1 depressive symptoms with T1 sexual function-
ing, etc.) and prospectively (T1 depressive symp-
toms and T2 and T3 sexual functioning, controlling
for T1 sexual functioning), controlling for relation-
ship status. By controlling for levels of the
dependent variable at T1, inferences can be made
about the direction of the causal inﬂuence.
Results
Population
Of the 70 patients diagnosed with testicular cancer
during the inclusion period in the Netherlands, 12
(17%) did not meet the inclusion criteria, and 3
were approached to late after orchiectomy. Six
patients decided not to participate (response5
90%). These non-participants did not diﬀer in age
from participants, but they did in treatment
modality. All non-participants received chemother-
apy, whereas a fourth of participants received
surgery only. After T1, 9 of the 49 (18%) patients
did not participate on all measurement times,
which means that complete data were available
from 40 out of 64 eligible patients. At the
MDACC, all patients with a possible diagnosis of
testicular cancer (n5 280) seen in the genitourinary
clinic were systematically screened. Of these, only
100 were eligible based on our eligibility require-
ments. Other reasons include not being newly
diagnosed, extragonadal primary, brain metas-
tases, too old or young, bilateral tumors, and
positive history of a major head injury. Seventy-six
patients consented to participate of whom 53
completed all assessments (response5 76%, 30%
dropout). The MDACC received no approval to
collect clinical and detailed sociodemographic data
from patients who chose not to participate in this
study. Therefore, no comparison between partici-
pants and non-participants was possible. In total,
data of 93 patients were analyzed.
Sociodemographic and treatment-related
variables
Mean age of all patients at T1 was 29.4 years
(standard deviation (SD)5 7.5), ranging from 18 to
50 years. Educational level completed varied from
primary school to advanced university degree, most
patients (30%) had a technical vocational degree or
some years of college. Of the patients, 74 (80%)
were employed for wages. Of the 19 who were not,
14 were students, 3 were unemployed, and 2 were
unable to work. At T3, twenty-four patients
(26%) had been treated with orchiectomy alone,
41 (44%) with orchiectomy and chemotherapy, and
28 (30%) were treated with additional RR1. More
than half of the patients were married or cohabit-
ing, 39% was single. (Table 1) Singles appeared to
be younger (t54.0, po0.001) and more often
unemployed (w25 12.3, po0.001) than patients
with a partner.
Preliminary analyses
It may be that diﬀerences exist between Holland
and the United States with respect to organization
of health care, education and work as well as for
social norms regarding dating behaviour and
establishing relationships. Analyses showed that
relationship status and employment status were
comparable in the two countries. Minor diﬀerences
were found with respect to age (UMCG patients
were somewhat younger than MDACC patients
(t52.0, po0.05)), educational level (MDACC
patients ﬁnished higher levels of education
(w25 12.8, po0.05)), and type of treatment
(UMCG patients more often receiving additional
abdominal surgery (w25 11.4, po0.01)). Repeated
measures analyses of variance with between-subject
factor nationality showed diﬀerences in erectile
function (F5 6.2, p5 0.015), sexual desire (F5 3.9,
p5 0.049), and overall satisfaction (F5 12.4,
p5 0.001) at some, but not all time points. There
were no signiﬁcant interactive eﬀects of nationality
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and time. To account for these diﬀerences found
and for other potential cultural covariates, a
nationality variable was retained in subsequent
analyses.
Effect of time on sexual functioning
Signiﬁcant time eﬀects were found on erectile
function, orgasmic function, intercourse satisfac-
tion, overall satisfaction and the total score.
Inspection of the mean scores showed that levels
of erectile function and intercourse satisfaction
were comparable at T1 and T2, but higher at T3.
Orgasmic function, overall satisfaction and the
total score followed a positive quadratic trajectory,
meaning that begin and end scores rise above the
center point. Levels decreased between T1 and T2,
and increased to an above T1 level at T3. Eﬀect
sizes of statistically signiﬁcant changes over time
were negligible indicating that changes were not
clinically signiﬁcant (Table 2).
Effect of relationship status
Repeated measures analysis of variance with
between-subject factor relationship status and
covariates age and employment status, indicated a
signiﬁcant group eﬀect on erectile and orgasmic
function, intercourse and overall satisfaction, and
the total score but not on level of desire. Singles
reported worse functioning than committed pa-
tients over the year. Eﬀect size for the diﬀerence in
intercourse satisfaction was small, and diﬀerences
in the other domains were negligible (Table 2).
There was a signiﬁcant interactive eﬀect of time
and relationship status on sexual desire (F5 7.4,
po0.01) and overall satisfaction (F5 7.3, po0.01),
indicating that desire and overall satisfaction
changed over time in diﬀerent ways for single and
committed patients. Inspection of the mean scores
showed that singles reported higher levels of desire
at T1 and T3 (not signiﬁcant) than committed
patients, and a comparable level at T2. Singles
experienced signiﬁcantly lower overall satisfaction
as compared with committed patients at all
measurement times, with the diﬀerence being
greatest at T1. With respect to the covariates
employment status and age, some eﬀects were
found. Employment status appeared to have an
eﬀect on orgasmic function (F5 5.5, po0.05),
sexual desire (F5 6.7, po0.05), intercourse satis-
faction (F5 4.8, po0.05) and the total score
(F5 4.3, po0.05). Age appeared to have an eﬀect
on sexual desire only (F5 8.1, po0.01). These
covariates contribute diﬀerently to sexual function-
ing as relationship status, but based on the size of
the F-values found, relationship status outweighs
these eﬀects.
Effect of treatment
Repeated measures analysis of variance, with
between-subject factor treatment, showed no sig-
niﬁcant group eﬀect or interactive eﬀect of group
and time on any aspect of sexual functioning
(Table 2).
Comparison with norm at T3
One year after diagnosis, sexual functioning of
patients did not diﬀer from norms, except for one
aspect: patients reported less overall satisfaction
(t5 2.8, po0.01) than norms (mean5 8.6,
SD5 1.7). The clinical relevance of this diﬀerence
Table 1. Sociodemographics at T1 and type of treatment received at T3
Total group N593 MDACC N5 53 UMCG N540 Norm n5109
Age (years) mean, (SD) 29.4 (7.5) 30.8 (7.7) 27.6 (6.8) 55
Range 18–50 18–51 18–43 29–76
Educational level N (%)
1 3 3% 3 6% — —
2 14 15% 10 19% 4 10%
3 12 13% 4 8% 8 20%
4 28 30% 15 28% 13 32%
5 23 25% 16 30% 7 18%
6 9 10% 2 4% 7 18%
7 4 4% 3 6% 1 2%
Relationship status N (%)
Single 36 39% 32 60% 15 38% —
Partner 57 61% 21 40% 25 68%
Employment status N (%)
Employed for wages 74 80% 41 77% 33 83% —
Not employed for wages 19 20% 12 23% 7 17%
Type of treatment N (%)
Surgery 24 26% 12 23% 12 30% —
Surgery1CT 41 44% 31 58% 10 25%
Surgery1CT1RRTM 28 30% 10 19% 18 45%
SD, Standard Deviation; CT, chemotherapy; RRRTM, resection of residual retroperitoneal tumormass.
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appeared small according to the eﬀect size
(d5 –0.4; 95% conﬁdence interval (ci): –0.7 to
0.12). Patients in a committed relationship
diﬀered from norms only on intercourse satisfac-
tion: patients reported more satisfaction (t52.2,
po0.05) than norms (mean5 10.6, SD5 3.9). The
clinical relevance of this diﬀerence appeared small
according to the eﬀect size (d5 0.33; ci: 0.0–0.66).
Singles reported worse erectile function (t5 3.3,
po0.01) than norms (mean5 25.8, SD5 7.6), less
intercourse satisfaction (t5 3.0, po0.01), and less
overall satisfaction (t5 2.6, po0.01). The clinical
relevance of these three diﬀerences was moderate
according to eﬀect sizes (erectile function:
d50.70, ci: 1.08 to 0.34; intercourse satisfac-
tion: d50.74, ci:1.1 to 0.36; overall satisfac-
tion: d50.56, ci: 0.93 to 0.19).
Depressive symptoms and sexual functioning
Depressive symptoms were highest at T1 (mean
11.6, SD 8.9) and decreased over time (T2:
mean5 9.9, SD5 8.6; T3: mean5 7.9, SD5 7.8)
(F5 20.6, po0.001). The change over time was,
however, negligible according to the eﬀect
size (0.18). At T1, 24 patients (26%) reported
clinically signiﬁcant depressive symptoms, at T2, 14
patients (15%), and at T3, 15 patients (16%) did.
Pearson’s product moment correlation coeﬃcients
between Times 1 and 2 (r5 0.58), Times 2 and 3
(r5 0.65), and Times 1 and 3 (r5 0.58) depressive
symptoms were signiﬁcant and strong. At T1, more
single patients (44%) reported clinically signiﬁcant
depressive symptoms than committed patients
(14%) (w25 10.7, po0.001), but percentages were
not signiﬁcantly diﬀerent at T2 (11 and 18%,
respectively) and T3 (17 and 16% respectively).
The percentages of patients reporting clinically
signiﬁcant depressive symptoms did not diﬀer
between the two treatment groups at T2 and T3
(treatment was similar for all patients at T1), or
between nationalities.
Partial correlations (controlled for relationship
status) were performed to examine concurrent and
prospective relationships between depressive symp-
toms and sexual functioning. At T1, depressive
symptoms were negatively related to one of the six
subscales of sexual functioning: weakly to overall
satisfaction (r50.28, po0.01). At T2, depressive
symptoms were negatively and weakly related to
erectile function (r50.21, po0.05), moderately
strongly related to overall satisfaction (r50.36,
po0.001), and negatively weakly to the total score
(r5 –0.21, po0.05). At T3 no signiﬁcant correla-
tions were found. Three signiﬁcant prospective
eﬀects of T1 depressive symptoms on T2 levels of
sexual functioning were found: for erectile function
(r50.24, po0.05), overall satisfaction
(r50.33, po0.01) and the total score (r5 0.23,
po0.05). For T3 no signiﬁcant prospective eﬀects
were found (Table 3).
Discussion
This longitudinal study focused on functional and
psychological sexual functioning in testicular can-
cer patients during the ﬁrst year after orchiectomy,
and on possible diﬀerences in sexual functioning
according to relationship status and depressive
Table 2. Descriptives on sexual functioning and repeated measures analyses of time and group effects
T1 T2 T3
Mean (SD) Mean (SD) Mean (SD)
Effect F p Effect size
Erectile function 21.6 (9.7) 21.0 (10.3) 24.1 (7.9) Time 4.8 0.03 0.05
Group: relationship status 26.5 0.000 0.19
Group: treatment 0.9 ns
Orgasmic functiona 7.8 (3.5) 6.9 (4.1) 8.4 (3.0) Time 8.7 0.004 0.09
Group: relationship status 6.9 0.01 0.08
Group: treatment 2.1 ns
Sexual desire 6.9 (1.9) 6.8 (2.1) 7.3 (1.7) Time 3.9 ns
Group: relationship status 0.33 ns
Group: treatment 1.4 ns
Intercourse satisfaction 8.2 (5.7) 7.9 (5.8) 10.0 (5.0) Time 7.7 0.007 0.08
Group: relationship status 29.1 0.001 0.26
Group: treatment 1.2 ns
Overall satisfactiona 7.7 (2.3) 7.1 (2.2) 7.9 (1.8) Time 10.7 0.002
Group: relationship status 10.2 0.002 0.12
Group: treatment 1.0 ns 0.10
Totala 53.4 (19.0) 50.3 (21.8) 58.2 (16.0) Time 7.2 0.009 0.08
Group: relationship status 14.4 0.001 0.16
Group: treatment 2.0 ns
ns, not significant.
aquadratic.
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symptoms. It appeared that sexual functioning
after testicular cancer ﬂuctuates during the ﬁrst
year after orchiectomy, but depressive symptoms
are no risk factors for sexual dysfunction. Singles
however did report more sexual problems than
committed men.
Testicular cancer patients experienced changes in
all aspects of sexual functioning, except in desire.
Apparently, in this group of young male cancer
patients, desire in sexual activity seems unaﬀected
by the cancer experience, at least during the ﬁrst
year. The other aspects of sexual functioning
changed over the year, but according to diﬀerent
patterns. Orgasmic functioning, overall satisfaction
and total sexual functioning changed according to
a u-shaped pattern. Patients reported decreased
functioning 3 months after removal of the aﬀected
testicle (which is the ending of chemotherapy cycles
for 75% of patients), followed by an increase in
sexual functioning to above baseline level 1 year
after diagnosis. Erectile functioning and inter-
course satisfaction were comparable directly fol-
lowing orchiectomy and 3 months later, and
patients reported improvement to above baseline
level after 1 year. When compared with norm
scores, patients only reported less overall satisfac-
tion. Clinical relevance of this decreased satisfac-
tion appeared to be small. However, even though
most aspects of functioning were comparable to
that of a norm group, this ﬁnding may be a cause
of concern as the norm group is an average of 25
years older.
A similar pattern was reported previously by
Fossa˚ and colleagues, who conducted a prospective
study with men diagnosed with metastatic testicu-
lar to examine the eﬀects of various chemotherapy
approaches on multiple functional domains, in-
cluding functional status. Their ﬁndings also
indicated that sexual functioning may be negatively
impacted after a testicular cancer diagnosis, but
tends to improve over time, regardless of treat-
ment [29]. It is possible that physical complaints,
psychological distress and recuperating from sur-
gery negatively aﬀected sexual functioning, and
that functioning improved after the patient was
treated and responding well and the immediate
threat was over. A comparable pattern was found
when testicular cancer survivors were asked to rate
their psychological functioning at the time of
study, and in retrospect prior to treatment and 6
months after treatment [30]. Apparently, both from
a retrospective as well as prospective view, patients
assess the months following end of treatment as
most stressful. It must be noted that even though
sexual functioning showed a decrease after treat-
ment, the overall change over the year was not
clinically signiﬁcant according to eﬀect sizes.
The present study showed that type of treatment
was unrelated to sexual functioning, which is in line
with previous studies on sexual functioning and
quality of life of testicular cancer patients
[5,8,12,16,17,31]. However, in other studies testi-
cular cancer patients reported worse functioning on
various quality of life domains, like physical
function and fatigue immediately after completion
of chemotherapy [29,32]. Perhaps increased under-
lying fatigue, which we did not include in the
present study, can explain the decreased orgasmic
functioning, overall satisfaction and total sexual
functioning at 3 months after orchiectomy.
The current study did show that relationship
status plays a role in explaining sexual functioning.
Single testicular cancer patients reported worse
sexual functioning over the year as compared with
patients with a partner in all but one aspect,
namely desire. Even though diﬀerences between
single patients and those in a relationship were
statistically highly signiﬁcant, eﬀect sizes indicated
that the diﬀerences were not clinically signiﬁcant. It
is likely that single men have intercourse less
frequently than committed men. Not being sexually
active can result in lower scores in the IIEF on
erectile functioning and intercourse satisfaction,
and that can partly account for the diﬀerence
between single and committed patients for these
aspects. While the desire to be sexually active was
the same in both groups (again underlining the idea
that desire is unaﬀected by the experience with
Table 3. concurrent and prospective relationships between depressive symptoms and sexual functioning
Concurrent ProspectiveCES-D
T1 T2 T3
CES-D and T2 sexual
functioning
CES-D and T3 sexual
functioning
r r r Partial ra Partial ra
Erectile function 0.20 0.21 0.10 0.24 0.01
Orgasmic function 0.13 0.15 0.15 0.01
Sexual desire 0.18 0.16 0.08 0.11 0.01
Intercourse satisfaction 0.10 0.12 0.16 0.02
Overall satisfaction 0.28 0.36 0.23 0.33 0.20
Total 0.20 0.21 0.10 0.23 0.01
acontrolled for T1 depressive symptoms and relationship status.
po0.05, po0.01, po0.001.
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cancer), singles evaluated their actual functioning
as worse. When compared with a norm group 1
year after surgery, singles also reported less overall
satisfaction, worse erectile functioning, and less
intercourse satisfaction. Eﬀect sizes were on the
verge of being clinically relevant for the latter two,
suggesting that functioning on these aspects is a
problem for singles. Men in a steady relationship at
the time of diagnosis often experience increased
intimacy with their partners [13,14,33], possibly
buﬀering negative feelings and consequences of
their treatment for testicular cancer. The ﬁnding
that patients in a relationship reported more
intercourse satisfaction than men in the norm
group may reﬂect this increased intimacy. Singles
might experience more insecurity about their
physical functioning because they miss this in-
timacy of a relationship. A second factor that may
explain the diﬀerence between single and com-
mitted patients might be fertility distress. Infertility
is a main concern for testicular cancer patients and
survivors, eventually aﬀecting approximately 30%
of survivors [34]. Even though sperm banking is
quite common before start of treatment, and
infertility can be assessed only after trying to
actively conceive for 1 year, concerns about
infertility may haunt testicular cancer patients in
the ﬁrst year after diagnosis. The testes are
associated with feeling strong and potent, and the
possibility of reproductive failure seems to decrease
the idea of a masculine identity [35,36]. Concerns
about possible infertility have been found to
negatively aﬀect sexuality and sexual functioning,
especially in singles, who might question whether
they will ﬁnd a partner [35].
The second possible risk factor for sexual
dysfunction examined was depression. Depression
was most prevalent directly following orchiectomy,
with 26% suﬀering from clinically elevated levels
indicating that they probably need professional
care. Later on in the year this percentage dropped
to 16 and is comparable to that found in an earlier
study [30]. Directly following orchiectomy, 44% of
the singles reported clinically elevated levels
of depressive symptoms as compared with 14%
of patients in a relationship, later on in the year no
diﬀerences were found. Being unmarried was also
found to be a risk factor for elevated depressive
symptoms in breast cancer patients [37]. Single
testicular cancer patients might lack the support a
partner may oﬀer during the most stressful period
of their illness, as men have been found to usually
draw the most support from their partner [38].
Shortly after orchiectomy, when depressive
symptoms were most prevalent, depression and
overall satisfaction were found to be related for
only one domain. Men who experienced more
depressive symptoms reported having less overall
satisfaction directly following orchiectomy. How-
ever, 3 months later, three domains of sexual
functioning were found to be related. Men who
experienced more depressive symptoms reported
having a worse erectile function, less overall
satisfaction and a lower overall sexual functioning
at this time. A year after diagnosis depressive
symptoms appeared unrelated to sexual function-
ing. Depressive symptoms seemed to have pre-
dictive power in later sexual functioning, but only 3
months after diagnosis. Depressive symptoms at
the time of diagnosis appeared to be predictive of
erectile function, overall satisfaction and overall
sexual functioning 3 months later. A year after
diagnosis no such predictive relationships were
found. Apparently, depressive symptoms are a
possible risk factor for sexual problems only
several months after diagnosis. Shortly after
diagnosis and 1 year later, depressive symptoms
are unrelated to sexual functioning. It might be
that testicular cancer patients are trying to return
to normal life when active treatment is over. At
that time, remaining depressive symptoms might be
most disturbing, also for sexual functioning.
Positive ﬁnding is that a year after diagnosis
depressive symptoms have decreased to normal
levels and appear to play no role in sexuality, at
least, not in testicular cancer patients.
This study has several limitations. Firstly, no
information was available on the functioning of
patients who declined to participate. They may
have been those who were functioning best or
worst, the results may have been biased in either
direction. Secondly, although nationality was con-
trolled for in the analyses, it might be that
diﬀerences in social norms regarding sexuality
between America and the Netherlands may inﬂu-
ence participants’ responses to the sexual function-
ing items. A larger study including patient groups
from several countries can address cultural inﬂu-
ences on sexuality after testicular cancer better
than a two-site study. On a related note, the
chemotherapy regimens oﬀered at UMCG and
MDACC were not identical, and the number of
participants in each of cells was not equal (i.e. there
were fewer participants who received orchiectomy
alone vs orchiectomy plus chemotherapy). While
we attempt to control for relevant site and
treatment variables in our analyses, cell size
imbalances may have inﬂuenced our ability to
describe the eﬀect between chemotherapy and
sexual function. Finally, comparisons with the
norm group should be made cautiously. In addi-
tion to being older than the testicular cancer
patients, the norm group consisted only of men
of unknown relationship status from North Amer-
ica. Thus, detailed comparisons were not possible.
Major strengths of the study were, however, the
use of a prospective study design, and the use of a
standardized, well-validated measure of sexual
function. Diﬀerent designs of studies on sexual
functioning generates diﬀerent ﬁndings. It was
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found earlier that an assessment made by patients
retrospectively indicated considerable sexual dete-
rioration after surgery for benign prostatic disease,
whereas a prospective assessment showed little
impact [39], possibly due to recall bias of the
respondents. It is also interesting that when
testicular cancer survivors were asked to describe
their baseline sexual functioning twice (ﬁrstly
before start of treatment, secondly at the time of
study), they evaluated their baseline sexual func-
tioning worse at the time of study than they did
before the diagnosis [30]. This ﬁnding could not be
supported by our prospective results, that mainly
showed signiﬁcant, but not clinically relevant
deterioration.
The positive ﬁndings of this study was that
sexual functioning appeared to have improved 1
year after orchiectomy and that the decreases
found were not clinically relevant. Men in a
relationship even reported more intercourse satis-
faction than norms. The fact that patients in a
relationship experienced similar functioning as the
norm group consisting of much older men, and
that single patients reported worse functioning
than men in the norm group is the reason for
concern however. Earlier studies showed that
impaired sexual functioning appears to remain
prevalent in approximately 15% of long-term
testicular cancer survivors [40]. We found that
one of the possible risk factors for sexual problems
was being single. This knowledge could facilitate
oﬀering information and possible guidance to those
who need it the most. Up to two-thirds of testicular
cancer patients still experience a strong need for
information concerning sexuality and one-ﬁfth
experienced a need for support on this matter,
even longer after treatment [41]. However, many
men ﬁnd talking about genitally related health
problems diﬃcult [42]. Health-care workers should
pay extra attention to single testicular cancer
patients, as they appeared more vulnerable to
experiencing sexual problems in the ﬁrst year after
diagnosis.
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